Title:Corrigendum to: UAE Consensus on Patient Profiles for Pre-exposure Prophylaxis with Monoclonal Antibodies against COVID-19 in Hematological Malignancies and Immunocompromised States
Volume: 5
Author(s): Shahrukh Hashmi*, Jehad Abdalla, Arif Raza Alam, Mohamed Abuhaleeqa, Amna Al Mehiri, Biju George, Amar Lal, Hani Yousif Osman and Panayotis Kaloyannidis
Affiliation:
- College of Medicine and Health Sciences, Khalifa University, Abu Dhabi, UAE
- Department of Medicine, Mayo Clinic, Rochester, MN, USA
Abstract:
The authors requested to update the acknowledgement,
funding, and authors contribution section in their article titled
“UAE Consensus on Patient Profiles for Pre-exposure
Prophylaxis with Monoclonal Antibodies against COVID-19 in
Hematological Malignancies and Immunocompromised States”
published in “New Emirates Medical Journal,” 2024; 5:
e02506882347591 [1].
We apologize for any inconvenience caused and
appreciate the opportunity to rectify this matter.
The original article can be found online at https://www.
eurekaselect.com/article/147185
Original:
AUTHORS’ CONTRIBUTIONS
It is hereby acknowledged that all authors have accepted
responsibility for the manuscript's content and consented to its
submission. They have meticulously reviewed all results and
unanimously approved the final version of the manuscript.
FUNDING
None.
ACKNOWLEDGEMENTS
Declared none.
Corrected:
AUTHORS’ CONTRIBUTIONS
S.H., J.A., A.R.A., M.A., A.Al.M., B.G., A.L., H.Y.O.,
P.K.: All contributed to the delphie and discus-sion meetings;
S.H., A.Al.M., A.R.A. and M.A.: Contributed to writing the
main manuscript; S.H., B.G., A.L., H.Y.O., P.K.: Contributed
to revising the main manuscript.
FUNDING
The consensus logistics and medical publication was
funded by AstraZeneca FZ LLC, Dubai, United Arab Emirates.
ACKNOWLEDGEMENTS
The authors extend their sincere gratitude to Meeting
Minds Medical Communications Agency for their unwavering
support in medical content development, including invaluable
editorial and formatting assis-tance, which significantly
contributed to the successful completion of the manuscript.
Additionally, we express our appreciation to the Emirates
Society of Hematology (ESH) for their endorsement of this
work, further enhancing its credibility and relevance within the
field. A courtesy copy of the final manuscript was provided to
AstraZeneca as a gesture of acknowledgment for their interest
in this research endeavor.
